| Code | CSB-RA012145MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to ramucirumab, designed to specifically target KDR (kinase insert domain receptor), also known as VEGFR-2 (vascular endothelial growth factor receptor 2). KDR is a critical receptor tyrosine kinase that mediates VEGF-induced endothelial cell proliferation, migration, and survival, playing a central role in both physiological and pathological angiogenesis. Overexpression or dysregulation of KDR signaling is implicated in tumor angiogenesis and progression across multiple cancer types, including gastric, colorectal, and non-small cell lung cancers, making it an important therapeutic target in oncology research.
Ramucirumab is a fully humanized IgG1 monoclonal antibody that binds to the extracellular domain of KDR, blocking VEGF ligand binding and subsequent receptor activation. This biosimilar antibody provides researchers with a valuable tool for investigating VEGF/VEGFR-2 signaling pathways, studying angiogenesis mechanisms, and exploring anti-angiogenic strategies in cancer biology and vascular disease models. It serves as an essential reagent for in vitro and in vivo studies examining tumor microenvironment dynamics and therapeutic resistance mechanisms.
There are currently no reviews for this product.